FDA Cardiovascular Indication Expansion and Dispensing of Semaglutide/Tirzepatide in CVD Patients With Overweight/Obesity
Dzuy Do(Truven Health Analytics (United States)), Nicholas L. Stucky(Bellevue College), Brianna M. Goodwin Cartwright(Bellevue Hospital Center), Mitsuaki Sawano(Yale New Haven Hospital), Lesley H. Curtis(Duke University), Samuel Gratzl(Bellevue College), Karthik Murugiah(Yale New Haven Hospital), Yuan Lu(Yale New Haven Hospital), Patricia J. Rodriguez(Bellevue College)
Cited by 0
Related Papers
Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity
|JAMA Internal Medicine|2024|268
Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity
|JAMA Network Open|2025|257
Perioperative Opioid Use and Chronic Post-Surgical Pain after Liver Transplantation: A Single Center Observational Study
|Journal of Cardiothoracic and Vascular Anesthesia|2019|25
Model-Based Algorithms for Detecting Peripheral Artery Disease Using Administrative Data From an Electronic Health Record Data System: Algorithm Development Study
|JMIR Medical Informatics|2020|25
The association of healthcare disparities and patient-specific factors on clinical outcomes in peripheral artery disease
|American Heart Journal|2021|18